Sage Journals: Discover world-class research

Abstract

This review aims to provide a comprehensive analysis of filgotinib, a selective Janus kinase 1 (JAK1) inhibitor, and its potential applications in the treatment of rheumatoid arthritis (RA). It assesses filgotinib’s efficacy, safety, and role compared to traditional disease-modifying antirheumatic drugs (DMARDs) and other JAK inhibitors. Authors conducted a systematic search of PubMed, Scopus and Google Scholar to identify relevant studies, including phase I, II, and III clinical trials. We extracted and synthesised data on efficacy end points (ACR20, ACR50, and ACR70), safety profiles, and long-term outcomes. We performed comparative analyses with traditional DMARDs and other JAK inhibitors. Filgotinib demonstrates high efficacy in RA management, with ACR20 response rates ranging from 70% to 80%, ACR50 from 40% to 50%, and ACR70 from 20% to 30%. It significantly reduces disease activity (as measured by DAS28-CRP) and improves physical function (as indicated by Health Assessment Questionnaire Disability Index [HAQ-DI] scores). Compared to traditional DMARDs, filgotinib offers superior efficacy and a favourable safety profile. In comparison to other JAK inhibitors, filgotinib’s selective JAK1 inhibition contributes to a similar or improved safety profile while maintaining high efficacy. Long-term data confirm its sustained benefits and manageable safety profile. Filgotinib is a promising treatment option for RA, offering significant benefits. Clinical trials have observed improvements in disease activity and quality of life. Its selective JAK1 inhibition and favourable safety profile make it a competitive alternative to both traditional DMARDs and other JAK inhibitors. Ongoing research into personalised medicine and emerging therapies will further define filgotinib’s role in RA management.

Keywords

Filgotinib JAK inhibitor rheumatoid arthritis clinical efficacy safety treatment outcomes

Introduction

Rheumatoid arthritis (RA) is an autoimmune disease-causing chronic inflammation of synovial joints, leading to painful swelling, stiffness and joint deformity.¹ It is a progressive condition that can cause severe physical disability if not managed. The disease’s pathogenesis involves genetic, environmental and immunological factors. The immune system attacks healthy joint tissues, causing inflammation and the release of pro-inflammatory cytokines.² RA affects individuals of any age, with a higher prevalence in women. It is associated with cardiovascular disease, lung involvement and increased infection risk, which complicate its management.³

Importance of Effective Management to Prevent Joint Damage and Disability

Effective management of RA is crucial to prevent irreversible joint damage and disability. The goal is to achieve and maintain clinical remission or low disease activity, improving physical function and patient quality of life. Early diagnosis and prompt initiation of disease-modifying antirheumatic drugs (DMARDs) are essential.⁴ Conventional DMARDs like methotrexate (MTX) are essential, but some patients may not achieve adequate disease control or experience adverse effects. Janus kinase (JAK) inhibitors, like filgotinib, offer an alternative to traditional DMARDs providing additional options for disease control and preventing long-term joint damage.

Introduction to Janus Kinase Inhibitors

Janus kinase (JAK) inhibitors represent a novel class of targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs). These agents interfere with the JAK-STAT signaling pathway, playing a critical role in modulating immune and inflammatory responses in rheumatoid arthritis.

Mechanism of Action of Janus Kinase Inhibitors

Janus kinase (JAK) inhibitors are synthetic pharmaceuticals that suppress the JAK-STAT signalling system. This is a crucial component of the immune response in RA. The JAK-STAT pathway is a crucial modulator of cytokine signalling, regulating immunological responses, haematopoiesis and inflammation.⁵. Four JAK enzymes phosphorylate specific STAT proteins, affecting gene expression in immune and inflammatory responses. Overactive JAK-STAT signalling in RA leads to pro-inflammatory cytokines, causing chronic inflammation. JAK inhibitors block this pathway, reducing inflammation and controlling the disease’s progression. These drugs are effective across multiple cytokines in RA, making them a potent option for patients (Figure 1).⁶

Figure 1.

Mechanism of Action of Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.

Overview of JAK Inhibitors Used in Rheumatoid Arthritis Treatment

JAK inhibitors represent a significant advancement in the treatment of RA, especially for patients who have an inadequate response to conventional DMARDs or biologic therapies. The following are the available treatment options or in development JAK inhibitors for the treatment of RA.

Tofacitinib (Xeljanz) is the first JAK inhibitor approved to treat RA. It primarily inhibits JAK1 and JAK3, with some activity against JAK2. By targeting these kinases, tofacitinib effectively reduces the production of pro-inflammatory cytokines like intetrleulin-6 (IL-6) and interferon-γ. Clinical trials have demonstrated its efficacy in reducing RA symptoms and slowing disease progression.⁷

Baricitinib (Olumiant) is a selective inhibitor of JAK1 and JAK2. Research has demonstrated its effectiveness in mitigating RA symptoms and enhancing physical function. Baricitinib’s inhibition of JAK1 and JAK2 decreases the activity of several cytokines, including IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), and interferon-γ. RA patients particularly note its role in reducing joint damage.⁸

Upadacitinib (Rinvoq) is a selective JAK1 inhibitor. It has been developed to a more targeted approach to JAK inhibition, aiming to minimise side effects while maintaining efficacy. Clinical studies have shown that upadacitinib effectively reduces RA symptoms and improves patients’ quality of life, making it a valuable option for RA treatment.⁹

Filgotinib is another selective JAK1 inhibitor under investigation for RA. It has shown promise in clinical trials, demonstrating significant efficacy in reducing disease activity and improving physical function. The selectivity of filgotinib for JAK1 aims to mitigate the risk of side effects commonly linked to broader JAK inhibition, including infections and blood disorders.¹⁰

Peficitinib is a pan-JAK inhibitor, meaning it targets multiple JAK enzymes. Asian populations, where it has received approval for use, have demonstrated its efficacy in treating RA. Peficitinib’s broader JAK inhibition may offer advantages in certain patient populations, but it also carries a higher risk of side effects.¹¹

Decernotinib: Researchers have studied decernotinib, a selective JAK3 inhibitor, for its potential in treating RA. While its development has been less prominent compared to other JAK inhibitors, it represents another avenue for targeted therapy in RA.¹²

Objectives of the Review

The primary objective of this systematic review is to thoroughly evaluate and synthesise the current evidence on the efficacy and safety of filgotinib in the treatment of RA. The review aims to:

Assess the Efficacy of Filgotinib

Analyse the effectiveness of filgotinib in achieving key clinical outcomes in RA, such as:

Improvement in disease activity scores

Response rates according to ACR20/50/70 criteria.

Reduction in radiographic progression of joint damage.

Enhancement of physical function and quality of life.

Evaluate the Safety Profile of Filgotinib

Investigate the incidence and severity of adverse events (AEs) associated with filgotinib, including:

Commonly reported side effects

Serious adverse events (SAEs)

Laboratory abnormalities

Compare Filgotinib with Other RA Treatments

Compare the efficacy and safety of filgotinib with other JAK inhibitors and biologic DMARDs.

Discuss filgotinib’s place in the treatment algorithm for RA, particularly in patients who have inadequate responses to conventional or biologic DMARDs.

Identify Patient Subgroups Benefiting from Filgotinib

Explore the efficacy and safety of filgotinib in specific patient populations, such as:

MTX-naive patients.

Patients with prior exposure to biologics or other JAK inhibitors.

Subgroups based on disease duration, severity, and comorbid conditions.

Highlight Gaps in Current Knowledge

Identify areas where further research is needed, including long-term safety studies and real-world effectiveness data.

Discuss the potential for filgotinib in combination therapy and its implications for personalised medicine in RA.

The ultimate goal of this review is to provide clinicians, researchers, and healthcare professionals with a detailed understanding of filgotinib’s role in RA treatment, guiding informed decision-making and optimising patient care.

Methodology

This review was conducted through a comprehensive literature search using databases such as PubMed, Scopus, and Google Scholar. Relevant clinical trials, review articles, and regulatory documents related to Filgotinib in rheumatoid arthritis were identified and critically analyzed (Figure 2).

Figure 2.

Methodology Overview of the Systematic Review Process.

Search Strategy

Databases used

We conducted the literature review using three databases: PubMed, Scopus, and Google Scholar. PubMed is a primary biomedical database for clinical trials and reviews relating to RA and pharmacological treatments. Scopus is a multidisciplinary database for peer-reviewed health sciences literature.

Keywords and search phrases

The search strategy used a combination of Medical Subject Headings (MeSH) terms and free-text keywords to capture relevant studies on filgotinib and its use in RA. It is intended that the following keywords and search phrases:

‘Filgotinib’, ‘Rheumatoid Arthritis’, ‘RA’, ‘Janus Kinase Inhibitor’, ‘JAK Inhibitor’, ‘Efficacy’, ‘Safety’, ‘Clinical Trials’, ‘Treatment’, ‘DMARD’

Inclusion and Exclusion Criteria

Studies were included if they focused on the efficacy, safety, or mechanism of action of Filgotinib in patients with rheumatoid arthritis. Articles not in English, case reports, and studies unrelated to Filgotinib or RA were excluded from the review.

The study selection process for this systematic review is outlined in Figure 3, which presents the PRISMA flow diagram illustrating the identification, screening, eligibility, and inclusion of studies evaluating Filgotinib in rheumatoid arthritis.

Figure 3.

PRISMA Flow Diagram for the Selection of Studies in the Systematic Review of Filgotinib in Rheumatoid Arthritis.

Types of studies included

Clinical Trials: Randomised controlled trials (RCTs), phase II/III trials, and open-label extension studies focusing on the efficacy and safety of filgotinib in RA patients.

Inclusion Criteria

Studies that assess the efficacy and/or safety of filgotinib in patients diagnosed with RA.

Studies published in peer-reviewed journals.

Articles published in English.

Studies with full-text availability.

Exclusion Criteria

Studies not focused on RA or that involve other conditions.

Preclinical studies (e.g., in vitro or animal studies).

Abstracts, letters, and editorials without substantial data.

Studies published in languages other than English.

Studies with insufficient data or those lacking proper methodological rigor.

Timeframe and Language Restrictions

The review focused on studies released between 2010 and present, which spans the development and study of JAK inhibitors, including filgotinib.

Data Extraction and Synthesis

Relevant data were systematically extracted from selected studies, including trial design, patient population, dosage, treatment duration, efficacy outcomes, and safety profiles. The findings were then synthesized to provide a comprehensive overview of Filgotinib's role in rheumatoid arthritis management.

Process of data collection

Data Extraction

We collected relevant information from each included study using a standardised data extraction form. Key data points included:

Study characteristics (e.g., authors, publication year, study design, sample size).

Patient demographics (e.g., age, gender, disease duration).

Treatment details (e.g., dosage, duration of treatment, concomitant therapies).

Efficacy outcomes (e.g., ACR response rates, DAS28 scores, radiographic progression).

Safety outcomes (e.g., incidence of adverse events, SAEs, laboratory abnormalities).

Quality Assessment

We evaluated the quality of included studies using appropriate tools, such as the Cochrane Risk of Bias tool for RCTs. This assessment helps ensure the reliability of the findings.

Clinical Efficacy of Filgotinib

Clinical trials evaluating Filgotinib have demonstrated its significant efficacy in improving symptoms of rheumatoid arthritis. Key outcomes such as ACR response rates, disease activity scores, and patient-reported improvements support its therapeutic potential in diverse patient populations.

Table 1 summarizes the clinical efficacy outcomes of Filgotinib reported across Phase I, II, and III trials, highlighting key parameters such as study design, dosing regimen and key findings.

Table 1.

Summary of Clinical Efficacy of Filgotinib Across Phase I, II and III Trials.

Sr. No	Study Phase	Study Name	Design	Dosing Regimen	Population	Key Findings	Ref.
1	Phase I	Phase I	Healthy volunteers and RA patients	Various doses	Healthy volunteers, RA patients	Well-tolerated; favourable pharmacokinetics; preliminary efficacy observed	¹³
2	Phase II	DARWIN 1	24-week, randomised, dose-ranging	Filgotinib 50 mg, 100 mg, 200 mg (once/twice daily)	RA patients with inadequate response to csDMARDs	Significant improvements in ACR20, ACR50, ACR70; higher doses showed greater efficacy; well-tolerated	¹⁴
3	Phase II	DARWIN 2	24-week, randomised, monotherapy	Filgotinib 50 mg, 100 mg, 200 mg (once daily)	RA patients with inadequate response to csDMARDs	Significant improvements in ACR20, ACR50 and ACR70 effective as monotherapy; similar safety profile to DARWIN 1	¹⁵
4	Phase III	FINCH 1	52-week, randomised, controlled	Filgotinib 100 mg, 200 mg (once daily); adalimumab; placebo	RA patients with inadequate response to methotrexate	Filgotinib 200 mg was found to be non-inferior to adalimumab in ACR20, ACR50 and ACR70; improvements in DAS28-CRP, HAQ-DI	¹⁶
5	Phase III	FINCH 2	24-week, randomised, controlled	Filgotinib 100 mg, 200 mg (once daily); placebo	RA patients with inadequate response to bDMARDs	Both doses of Filgotinib were significantly better than placebo in ACR20, ACR50 and ACR70; 200 mg showed greatest benefit	¹⁷
6	Phase III	FINCH 3	52-week, randomised, controlled	Filgotinib 100 mg, 200 mg (once daily); methotrexate	Methotrexate-naive RA patients	Significant improvements in ACR20, ACR50 and ACR70. Combination therapy was slightly more effective than monotherapy; both were superior to methotrexate alone	¹⁸

Efficacy End Points

As shown in Table 2, Filgotinib demonstrated consistent efficacy across various clinical trials, with notable improvements in ACR20, ACR50, and ACR70 response rates, reflecting its potential in reducing disease activity in patients with rheumatoid arthritis.

Table 2.

Efficacy End Points of Filgotinib in Rheumatoid Arthritis (ACR20, ACR50, ACR70 Response Rates).

Sr. No	End Point	Definition	Filgotinib 200 mg Results	Placebo Results	Comparison to Other JAK Inhibitors	Measurement Timeline	Statistical Significance	Ref.
1.	ACR20	20% improvement in the number of tender/swollen joints plus a 20% improvement in 3 of 5 criteria (global assessments, pain scale, physical function, acute-phase reactants)	70%–80%	30%	Comparable efficacy to other JAK inhibitors; effective	Week 12	P < .001	^19–20
2.	ACR50	50% improvement in the same criteria	40%–50%	15%	Comparable to other JAK inhibitors; substantial improvement	Week 12	P < .001	^19–20
3.	ACR70	70% improvement in the same criteria	20%–30%	5%	Comparable; indicates significant clinical improvement	Week 12	P < .001	^19–20
4.	DAS28-CRP	Disease Activity Score based on 28 joints, incorporating C-reactive protein	Significant reduction	Minimal reduction	Effective in reducing disease activity	Week 12	P < .001	^19–21
5.	HAQ-DI	Health Assessment Questionnaire-Disability Index, measuring physical function and disability	Notable improvement	Minor improvement	Enhanced physical function and quality of life	Week 12	P < .01	^19–21

Comparative Efficacy

Comparative studies have assessed Filgotinib against other JAK inhibitors and conventional DMARDs to determine its relative effectiveness. These evaluations help position Filgotinib within the broader RA treatment landscape, highlighting its strengths and limitations.

Comparison with Traditional DMARDs

Filgotinib’s efficacy and safety profile have been compared with traditional disease-modifying antirheumatic drugs (DMARDs) like methotrexate. These comparisons offer valuable insights into its potential advantages in terms of symptom relief, disease progression control, and patient tolerability.

Table 3 presents a comparative analysis of Filgotinib versus traditional disease-modifying antirheumatic drugs (DMARDs), highlighting its superior or comparable efficacy in improving clinical outcomes among patients with rheumatoid arthritis.

Summary

Filgotinib, ACR20 the proportion of individuals with a 20% enhancement in RA symptoms. In phase III studies, including the FINCH trials, filgotinib has demonstrated ACR20 response rates ranging from 70% to 80%, contingent upon dose and patient demographics. The proportion of patients attaining a 50% enhancement. Filgotinib has had ACR50 responses of around 40%-50% (Table 3).

Table 3.

Comparative Efficacy of Filgotinib Versus Traditional DMARDs in Rheumatoid Arthritis.

Sr. No	Medication	Efficacy (ACR20/ 50/70 Response Rates)	Disease Activity Score (DAS28-CRP) Reduction	Health Assessment Questionnaire (HAQ-DI) Improvement	Safety Profile	Ref.
1	Filgotinib	ACR20:70%–80%, ACR50: 40%–50%, ACR70: 20%–30%	Significant reduction	Notable improvement	Generally well-tolerated; similar adverse effects to other JAK inhibitors	^19–20
2	Methotrexate (MTX)	ACR20: ~50%–60%, ACR50: ~30%, ACR70: ~15%	Moderate reduction	Moderate improvement	Well-established safety profile; side effects include gastrointestinal symptoms and liver toxicity.	²²
3	Sulfasalazine	ACR20: ~50%–60%, ACR50: ~20%–30%, ACR70: ~10%	Moderate reduction	Moderate improvement	Generally well-tolerated; side effects include gastrointestinal issues and rash	²³
4	Leflunomide	ACR20: ~50%–60%, ACR50: ~25%–35%, ACR70: ~15%	Moderate reduction	Moderate improvement	Side effects include liver toxicity and gastrointestinal issues	²⁴

Filgotinib demonstrated ACR70 response rates of 20%-30%, resulting in a 70% improvement.^19–20

Filgotinib monotherapy did not have a superior ACR20 response rate versus MTX. Filgotinib was well tolerated, with acceptable safety compared with MTX.¹⁸

Comparison with Other JAK Inhibitors

Filgotinib has been evaluated alongside other JAK inhibitors such as tofacitinib, baricitinib, and upadacitinib. These comparisons help to highlight differences in selectivity, clinical efficacy, safety profiles, and tolerability, which are essential for guiding treatment decisions in rheumatoid arthritis.

Table 4 summarizes the comparative efficacy of Filgotinib against other Janus kinase (JAK) inhibitors, illustrating differences in clinical response rates, remission outcomes, and safety profiles across key phase II and III trials in rheumatoid arthritis.

Table 4.

Comparative Efficacy of Filgotinib Versus Other JAK Inhibitors in Rheumatoid Arthritis.

Sr. No	JAK Inhibitor	Efficacy (ACR20/50/70 Response) Rates	Disease Activity Score (DAS28-CRP) Reduction	Health Assessment Questionnaire (HAQ-DI) Improvement	Safety Profile	Ref.
1	Filgotinib	ACR20: 70%–80%, ACR50: 40%–50%, ACR70: 20%–30%	Significant reduction	Notable improvement	Generally well-tolerated; selective for JAK1	^19–21
2	Tofacitinib	ACR20: ~50%–60%, ACR50: ~30%–40%, ACR70: ~15%–20%	Moderate-to- significant reduction	Moderate-to-notable improvement	Broader JAK inhibition; increased risk of infections and lipid abnormalities	²⁵
3	Baricitinib	ACR20: ~60%–70%, ACR50: ~30%–40%, ACR70: ~15%–20%	Significant reduction	Notable improvement	Inhibits JAK1 and JAK2; risk of anaemia and thrombocytopenia	²⁶
4	Upadacitinib	ACR20: ~60%–70%, ACR50: ~40%–50%, ACR70: ~20%–25%	Significant reduction	Notable improvement	Selective for JAK1; risk profile similar to filgotinib	²⁷

Summary

Studies have demonstrated that filgotinib exhibits a favourable safety and efficacy profile outperforming other JAK inhibitors in specific measures like ACR response rates and safety profiles. For instance, in the FINCH 3 trial, filgotinib showed promise in terms of ACR20, ACR50 and ACR70 response rates, with similar or better results in some subgroups compared to tofacitinib and baricitinib. It is believed that filgotinib’s selectivity for JAK1 contributes to its reduced risk of SAEs, which includes fewer reported cases of serious infections and malignancies.

Tofacitinib and baricitinib exhibit similar efficacy but have broader or less selective inhibition profiles, potentially affecting their safety profiles differently.

Upadacitinib also shows high efficacy with a selective JAK1 profile, providing benefits similar to filgotinib with a comparable safety profile.

Overall Comparison

Filgotinib stands out for its selective inhibition of JAK1, potentially contributing to its efficacy and reduced side effects compared to non-selective JAK inhibitors.

Other JAK inhibitors like tofacitinib, baricitinib and upadacitinib provide similar benefits but have varying safety profiles and selectivity that can influence clinical decision-making based on individual patient needs.

Serious Infections and Outcomes with Filgotinib

The risk of serious infections is a critical consideration with JAK inhibitors, including Filgotinib. Clinical trials and long-term studies have evaluated the incidence, types, and outcomes of serious infections associated with Filgotinib use, providing important safety insights for clinical practice.

Percentage of Patients Experiencing Serious Infections: The prevalence of severe infections among individuals utilising filgotinib in clinical trials is around 1%-2% during a 24-week period. These infections generally encompass pneumonia, urinary tract infections, bronchitis and cellulitis and are analogous to those observed with other JAK inhibitors.²⁸

Outcomes Associated with These Infections: While severe infections pose a known danger, appropriate medical care can adequately control the majority of cases. Elderly individuals or those with comorbidities may experience more severe results, such as hospitalisation. The overall fatality rate from severe infections in individuals administered filgotinib remains low in the examined studies.

Comparison with Tofacitinib and Other JAK Inhibitors

Comparative studies between Filgotinib and other JAK inhibitors, such as Tofacitinib, have highlighted differences in efficacy, safety profiles, selectivity for JAK isoforms, and patient-reported outcomes. These comparisons are essential for informed clinical decision-making and personalized treatment approaches in rheumatoid arthritis management.

Tofacitinib: Clinical studies indicate a greater prevalence of severe infections associated with Tofacitinib relative to filgotinib, with an incidence rate of around 3%-4% over the same 24-week duration. The extensive inhibition of several JAK enzymes (JAK1 and JAK3) by tofacitinib is believed to elevate this risk.

Baricitinib has an infection rate of 2%-3%, with a specific risk for herpes zoster infections.²⁸

Upadacitinib: Like filgotinib, upadacitinib has a high infection rate of 1%-2%, which is very similar to filgotinib because it blocks JAK1.

Long-term Efficacy

Table 5 presents the long-term treatment outcomes of Filgotinib in patients with rheumatoid arthritis, highlighting study design, population, key finding and patient-reported outcomes over extended follow-up periods in clinical trials.

Table 5.

Long-Term Treatment Outcomes of Filgotinib in Rheumatoid Arthritis.

Sr. No	Study	Design	Population	Duration	Key Findings	Ref.
1	DARWIN 3	Open-label, long-term extension	Patients from DARWIN 1 and 2 trials	8.2 years andUp to 4 years	• Sustained ACR20, ACR50 and ACR70 response rates• Consistently low DAS28-CRP scores• Continued HAQ-DI improvement	^30–31
2	FINCH 4 Study	Open-label, long-term extension	Patients from FINCH 1, 2 and 3 trials	Up to 6 years	• Consistent ACR response rates• Sustained inhibition of radiographic progression• Continued improvement in patient-reported outcomes• Maintained ACR response rates• Persistently low disease activity• Long-term safety profile consistent with previous studies	^32–33

Long-term efficacy is crucial in understanding the sustainability of a drug’s benefits over time, especially in chronic conditions like RA. Long-term extension studies have evaluated filgotinib, a selective JAK1 inhibitor, to assess its prolonged effectiveness and safety.²⁹

Safety and Tolerability

The safety and tolerability profile of Filgotinib has been extensively evaluated in clinical trials. This section summarizes common adverse events, serious risks, and the overall benefit-risk assessment associated with its use in rheumatoid arthritis.

Table 6 summarizes the safety and tolerability profile of Filgotinib in rheumatoid arthritis, including the incidence of adverse events, serious infections, and laboratory abnormalities observed across clinical studies.

Table 6.

Safety and Tolerability Profile of Filgotinib in Rheumatoid Arthritis.

Sr. No	Category	Details	Ref.
1.	Adverse effects	Common adverse effects: • Infections: upper respiratory tract infections, nasopharyngitis • Gastrointestinal: Diarrhoea, nausea • Haematologic: anaemia, neutropenia	^34–35
2.	Serious adverse events (SAEs)	• Infections: Serious infections are reported in a small percentage of patients, including pneumonia and herpes zoster • Malignancies: Rare cases of malignancies have been reported, though the incidence is comparable to that of other JAK inhibitors	^36–37
3.	Long-term safety data	• Long-term safety: Sustained safety profile over multiple years of treatment • No new safety signals were identified in long-term extension studies • Similar incidence of serious adverse events as in short-term studies	^31–33

Types of Malignancies Linked to Filgotinib

The overall malignancy risk with filgotinib appears to be relatively low. Long-term safety data from studies such as DARWIN-1–3 and FINCH-1 have reported a malignancy rate of approximately 1.5%-1.8%. Research indicates that people with RA exhibit an elevated incidence of malignancies, particularly among those on immunosuppressive treatment, in comparison to the general population. The trial recruited 739 of the 790 patients who completed the phase II parent investigations. Out of the 13 people who had cancer that got worse without treatment, four had blood cancer (3 non-Hodgkin lymphoma and 1 diffuse large B-cell lymphoma) and nine had solid tumours (2 lung cancers, 2 breast cancers, and 1 each of colon cancer, gallbladder adenocarcinoma, metastatic leiomyosarcoma, melanoma and kidney cancer).³¹

Clinical Applications

Filgotinib has demonstrated significant therapeutic potential in the management of moderate-to-severe rheumatoid arthritis. This section discusses its approved indications, recommended usage, and its role in clinical practice based on current evidence.

Patient Populations

Filgotinib is effective in treating RA in both younger and older patients, with consistent efficacy across age groups. Its safety profile is similar to younger populations, making it a viable option for all age groups.

Clinical trials have evaluated filgotinib across a broad range of age groups, primarily focusing on adults with moderate to severe RA. Most of the studies have included patients aged 18–75 years, with older populations (≥65 years) being a key subgroup of interest given the age-related risks for RA and the potential for increased susceptibility to adverse events in older adults.

While the drug has shown efficacy in both younger and older adults, post-hoc analyses of clinical trials, including the FINCH 1, 2 and 3 studies, suggest that filgotinib is particularly well-tolerated in older patients, showing a favourable safety profile compared to other JAK inhibitors. Importantly, older patients did not exhibit a higher incidence of SAEs compared to younger patients, which is a significant consideration given the increased risks for infections or other complications in elderly populations. However, further real-world data on long-term safety and efficacy, particularly in patients over 75 years old, would be valuable.²⁹

Combination Therapy

Researchers have thoroughly investigated filgotinib in conjunction with MTX for individuals exhibiting insufficient response to MTX alone. The combined treatment has demonstrated increased effectiveness, enhancing ACR response rates, DAS28-CRP and physical function. It possesses a well-accepted safety profile.¹⁸

Researchers have also studied the safe combination of filgotinib with other DMARDs like sulfasalazine and leflunomide for additional disease control benefits. This combination may offer an effective treatment strategy for patients.³⁸

Monotherapy

Filgotinib is a potent monotherapy for RA patients, particularly those with MTX insensitivity or contraindications.¹⁸ Clinical trials show significant improvements in ACR20, ACR50 and ACR70 response rates, with the 200 mg dose being particularly effective.^17–18

Comparative Analysis

A thorough comparative analysis of Filgotinib with other conventional and novel therapies provides valuable insights into its relative efficacy, safety, and clinical utility. This section highlights key differences and similarities with alternative treatment options.

Table 7 presents a comparative analysis of the long-term safety and efficacy profiles of Filgotinib versus other JAK inhibitors and biologic DMARDs, highlighting key differences in clinical outcomes and adverse event rates reported in extended follow-up studies.

Comparative Analysis: Filgotinib versus Other JAK Inhibitors and Biologic DMARDs

Table 7.

Comparative Analysis of Long-Term Safety and Efficacy of Filgotinib Versus Other JAK Inhibitors and Biologic DMARDs.

Sr. No	Comparison (Filgotinib vs.)	Efficacy in ACR Response Rates	Long-Term Safety Data (Adverse Event Rates, Serious Infections, Malignancies)	Disease Activity Score (DAS28-CRP) Reduction	Health Assessment Questionnaire (HAQ-DI) Improvement	Ref.
1.	Tofacitinib	Filgotinib:ACR20–70%–80%ACR50–40%–50%ACR70–20%–30%Tofacitinib:ACR20–50%–60%ACR50–30%–40%ACR70–15%–20%	Filgotinib: Lower incidence of serious infections.Tofacitinib: Higher risk of lipid abnormalities, increased infections	Filgotinib: Significant reduction.Tofacitinib: Moderate-to-significant reduction	Filgotinib: Notable improvementTofacitinib: Moderate-to-notable improvement	^19–21 ²⁵
2.	Baricitinib	Filgotinib:ACR20–70%–80%ACR50–40%–50%ACR70–20%–30%Baricitinib:ACR20–60%–70%ACR50–30%–40%ACR70–15%–20%	Filgotinib: Favourable safety profile.Baricitinib: Risk of anaemia, thrombocytopenia	Both show significant reduction	Both show notable improvement	^19–21 ²⁶
3.	Upadacitinib	Filgotinib:ACR20–70%–80%ACR50–40%–50%ACR70–20%–30%Upadacitinib:ACR20–60%–70%ACR50–40%–50%ACR70–20%–25%	Filgotinib: Fewer serious adverse events.Upadacitinib: Similar safety profile	Both show significant reduction	Both show notable improvement	^19–21 ²⁷
4.	Adalimumab (Biologic DMARD)	Filgotinib:ACR20–70%–80%ACR50–40%–50%ACR70–20%–30%Adalimumab:ACR20–50%–60%ACR50–30%–40%ACR70–15%–20%	Filgotinib: Oral, fewer infections.Adalimumab: Injectable, higher infection rates over the long term	Both show significant reduction	Both show notable improvement	^19–21 ^16,39
5.	Etanercept (Biologic DMARD)	Filgotinib:ACR20–70%–80%ACR50–40%–50%ACR70–20%–30%Etanercept:ACR20–60%–70%ACR50–30%–40%ACR70–15%–20%	Filgotinib: Oral, fewer infections.Etanercept: Higher risk of infections over the long term	Both show significant reduction	Both show notable improvement	^19–21 ⁴⁰

Economic Considerations

This section evaluates the economic implications of Filgotinib therapy in the management of rheumatoid arthritis. It includes an analysis of cost-effectiveness, direct and indirect healthcare expenditures, and comparative pricing relative to other JAK inhibitors and biologic DMARDs, providing insights into its value proposition in clinical practice.

Cost-effectiveness

The cost-effectiveness of Filgotinib is assessed by examining its clinical benefits relative to its financial burden on healthcare systems. This includes evaluating quality-adjusted life years (QALYs), healthcare resource utilization, and treatment affordability compared to alternative JAK inhibitors and conventional DMARDs.

Direct Cost

Filgotinib’s procurement cost is comparable to other JAK inhibitors, but its oral administration method may reduce healthcare costs due to infusion procedures. Its dose schedule allows for more flexible patient care, potentially reducing hospital visits.

Indirect Cost

Filgotinib’s effectiveness in alleviating pain and inflammation can markedly enhance patients’ quality of life, perhaps resulting in heightened productivity and decreased job absenteeism. This enhancement can yield significant economic advantages for both patients and companies. Moreover, proficient management of RA symptoms might mitigate the likelihood of comorbidities, thereby reducing long-term healthcare expenditures.

Comparative Effectiveness

Economic evaluations comparing filgotinib with other JAK inhibitors have shown that it may provide superior health outcomes at a comparable or lower cost. Studies indicate that filgotinib can lead to greater improvements in quality-adjusted life years (QALYs) due to its favourable safety profile and effectiveness, making it a cost-effective choice in RA management.⁴¹

Pharmacoeconomic models that incorporate data from clinical trials and real-world studies have generally concluded that filgotinib is a cost-effective treatment for RA.⁴¹ These models often demonstrate that, despite its initial cost, the long-term benefits in terms of improved health outcomes and reduced healthcare utilisation justify its use.

Healthcare Utilisation

Filgotinib’s effectiveness in managing RA may lead to reduced healthcare utilisation compared to traditional DMARDs and other JAK inhibitors. Patients on filgotinib experience fewer disease flares and hospitalisations, resulting in lower healthcare costs. Studies suggest that filgotinib can contribute to significant cost savings by reducing the need for additional medications and interventions. It also improves patient quality of life, leading to enhanced physical function and reduced disease symptoms, potentially reducing indirect costs.

Future Directions

Future research on Filgotinib should focus on long-term safety outcomes, head-to-head comparative trials with other JAK inhibitors, and its effectiveness in diverse patient subpopulations. Additionally, studies exploring biomarkers for treatment response and real-world cost-benefit analyses will be crucial to optimizing its clinical utility.

Ongoing Research

Current studies include extended trials to investigate the long-term safety and effectiveness of filgotinib, its impact on comorbid conditions and real-world patient populations. Researchers are investigating combination therapies with other RA treatments to evaluate synergistic effects and optimise treatment regimens. To make filgotinib a better RA treatment, researchers are studying how it works by looking at how it affects certain immune pathways and how it interacts with other signalling molecules.⁴²

Research is exploring alternative formulations of filgotinib to improve patient adherence and ease of use, such as extended-release formulations or combination therapies. Additionally, studies are assessing its potential for treating other autoimmune diseases beyond RA.

Personalised Medicine

Progress in genetics and biomarker research is facilitating personalised therapy strategies for RA, enhancing results and reducing unwanted effects.⁴³ Researchers are formulating prediction models utilising genetic and clinical data to enhance therapy and dose optimisation. The clinical integration of personalised medicine necessitates guidelines and tools to assist physicians in making educated decisions based on genetic and biomarker data.⁴⁴.

Innovative Therapies

Researchers are developing new JAK inhibitors with improved selectivity and safety profiles, which could potentially offer enhanced efficacy and reduced side effects compared to current options like filgotinib. Cell-based therapies, like CAR T-cell therapy and stem cell therapy, offer potential disease-modifying benefits for RA patients.⁴⁵

Potential Impact

Innovative therapies and personalised medicine approaches could improve disease management, leading to better long-term outcomes, reduced disability and improved quality of life for RA patients. These changes could shift treatment paradigms, offering more targeted and effective options.

Discussion

Filgotinib is a viable therapeutic option for individuals with RA, especially for those who have not sufficiently reacted to conventional DMARDs. As a second-line treatment after DMARDs, filgotinib offers unique benefits due to its specific inhibition of Janus kinase 1 (JAK1), setting it apart from conventional DMARDs and other JAK inhibitors.

Efficacy and response rates in clinical investigations have shown that filgotinib attains superior response rates and enhanced physical function relative to conventional DMARDs and non-selective JAK inhibitors. The medicine has demonstrated notable enhancements in ACR response rates and decreases in disease activity, rendering it a viable option for individuals necessitating more intensive treatment approaches.

Dosing guidelines recommend administering 200 mg of filgotinib once a day. Individual patient response and tolerability may modify this regimen, facilitating tailored treatment programmes that account for patient-specific characteristics and illness severity.

Filgotinib’s specific mode of action enhances its favourable safety profile. It is less likely for filgotinib to cause side effects like hepatotoxicity, dyslipidaemia, cytopenias, thromboembolic events and infections than other JAK inhibitors. This advantageous safety profile increases its appeal as a therapy alternative, especially for those susceptible to severe problems.

Particular advantages of filgotinib surpass its effectiveness and safety. Selective inhibition of JAK1 not only controls disease activity but also lowers the risk of serious side effects that are often linked to non-selective JAK inhibitors. Furthermore, filgotinib may offer potential steroid-sparing benefits, a crucial benefit for individuals requiring prolonged corticosteroid treatment.

Customised therapeutic approaches in the future for RA care may incorporate more individualised treatment strategies, including genetic indicators to forecast responses to filgotinib. Further research is necessary to identify specific indicators that could inform treatment decisions and improve outcomes for individual patients.

Despite the promising data on filgotinib, gaps remain in long-term efficacy and safety data. More research required for head-to-head trials to determine its comparative effectiveness against other JAK inhibitors. Ongoing research into next-generation JAK inhibitors and emerging therapies will further clarify filgotinib’s role in RA management and potentially expand its applications.

Conclusion

Filgotinib is a highly effective treatment for RA with high ACR response rates, substantial reductions in disease activity and improvements in physical function. It offers superior efficacy and a favourable safety profile compared to traditional DMARDs. Filgotinib’s selective JAK1 inhibition reduces side effects, making it a strong candidate for RA management. Its safety profile is comparable to or better than other JAK inhibitors, but ongoing monitoring is essential for long-term adverse effects. Filgotinib’s high efficacy and potential reduction in healthcare utilisation and costs support its cost-effectiveness, despite its higher cost.

It looks like filgotinib could be a big step forward in treating RA. It has a lot of advantages over older DMARDs and works just as well as other JAK inhibitors. As research continues, it will play a crucial role in future RA management strategies. Tailoring personalised medicine based on genetic and biomarker information could enhance filgotinib’s efficacy and optimise patient outcomes. Additionally, research into innovative therapies and next-generation treatments will complement filgotinib’s role in RA management, providing clinicians with a broader range of treatment options.

List of Abbreviations

RA: Rheumatoid arthritis

JAK: Janus kinase

DMARDs: Disease-modifying antirheumatic drugs

ACR: American College of Rheumatology

DAS28-CRP: Disease Activity Score in 28 Joints - C-Reactive Protein

HAQ-DI: Health Assessment Questionnaire-Disability Index

MTX:: Methotrexate

SAE: Serious adverse events

bDMARDs: Biologic disease-modifying antirheumatic drugs

csDMARDs: Conventional synthetic disease-modifying antirheumatic drugs

RCT: Randomised controlled trial

FDA: Food and Drug Administration

EMA: European Medicines Agency

PK: Pharmacokinetics

Footnotes

Acknowledgements

The author expresses sincere gratitude to Krescent Medical Research Pvt. Ltd. for their invaluable guidance and support throughout the preparation of this manuscript.

Authors’ Contribution

All authors contributed substantially to the conceptualization, drafting, and critical revision of this manuscript.

Dr. Krishnaa S. Upadhye: Conceptualized the study, defined the design and intellectual content, conducted comprehensive literature searches, supervised clinical and experimental aspects, acquired relevant data, and took the lead in manuscript preparation, editing, and review. Dr. Upadhye also served as the guarantor for the integrity and accuracy of the work.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Data Availability

Not applicable as no new data were generated or analyzed for this review article.

Declaration of Conflicting Interests

Dr. Krishnaa S. Upadhye is the Director of Clinical Operations at Krescent Medical Research Pvt. Ltd. This affiliation has been disclosed to the journal and the publisher. Krescent Medical Research Pvt. Ltd. had no role in the conceptualization, writing, or approval of this manuscript, and no funding was received from the company for this work. The views expressed in this review article are solely those of the author and do not necessarily reflect the views of Krescent Medical Research Pvt. Ltd.

Ethical Considerations

Not applicable.

Funding Statement

The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

References

Hughes-Austin

, Ix

, Ward

, . Associations of joint swelling, joint stiffness, and joint pain with physical activity in first-degree relatives of patients with rheumatoid arthritis. medRxiv. 2020. doi: 10.1101/2020.06.13.20130526.

Hemati

, Rahimis

. Pathophysiology of rheumatoid associated lung diseases. Biomed J Sci Tech Res. 2020;30 (1): 22986–22992.

Crowson

, Matteson

, Myasoedova

, . The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheumatism. 2011;63(3):633–639.

Monti

, Montecucco

, Bugatti

, Caporali

. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open. 2015;1(Suppl 1):e000057.

Papp

, Menter

, Raman

, . A randomized phase 2b trial of baricitinib, an oral janus kinase (jak) 1/jak2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174(6):1266–1276.

Sanchez

, Fernandes

, Palomino

. The JAK-STAT pathway and the JAK inhibitors. J Clin Res Dermatol. 2020;7(5):1–6.

Taylor

. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology. 2019;58(Supplement_1):i17-i26.

McInnes

, Byers

, Higgs

, . Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183.

Tanaka

. A review of Upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020;30(5):779–787.

10.

Mysler

, Lizarraga

. Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis. Rheumatology. 2021; 60(Supplement_2):ii17-ii23.

11.

Kivitz

, Gutiérrez-Ureña

, Poiley

, . Peficitinib, a JAK inhibitor, in the treatment of moderate–to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheumatol. 2017;69(4):709–719.

12.

Westhovens

Clinical efficacy of new JAK inhibitors under development. Just more of the same?

Rheumatology (Oxford). 2019;58(Suppl 1):i27-i33.

13.

Namour

, Diderichsen

, Cox

, . Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54(8):859–874.

14.

Westhovens

, Taylor

, Alten

, . Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017;76:998–1008.

15.

Kavanaugh

, Kremer

, Ponce

, . Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017;76:1009–1019.

16.

Combe

, Kivitz

, Tanaka

, . Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80:848–858.

17.

Genovese

, Kalunian

, Gottenberg

, . Effect of Filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 Randomized Clinical Trial. JAMA. 2019;322(4):315–325.

18.

Westhovens

, Rigby

, Heijde

, . Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021;80(6):727–738.

19.

Combe

, Tanaka

, Buch

, . Efficacy and safety of Filgotinib in patients with high risk of poor prognosis who showed inadequate response to MTX: a post hoc analysis of the FINCH 1 Study. Rheumatol Ther. 2023;10(1):53–70.

20.

Curtis

, Emery

, Downie

, . Filgotinib demonstrates efficacy in rheumatoid arthritis independent of smoking status: post hoc analysis of phase 3 trials and claims-based analysis. Rheumatol Ther. 2024;11(1):177–189.

21.

Aletaha

, Westhovens

, Gaujoux-Viala

, . Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3. RMD Open. 2021;7(2):e001621.

22.

Rubio-Romero

, Díaz-Torné

, Moreno-Martínez

, . Methotrexate treatment strategies for rheumatoid arthritis: a scoping review on doses and administration routes. BMC Rheumatol. 2024;8:11.

23.

Hattori

K Kanayama

. Efficacy of sulfasalazine monotherapy in patients with rheumatoid arthritis who had factors associated with preference for sulfasalazine over methotrexate as the first-line drug. Ann Rheum Dis. 2023;82:1448.

24.

Strand

, Cohen

, Schiff

, . Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med. 1999;159(21):2542–2550. doi: 10.1001/archinte.159.21.2542.

25.

Fleischmann

, Kremer

, Cush

, . Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. New Eng J Med. 2012;367(6):495–507.

26.

Caporali

, Taylor

, Aletaha

, . Efficacy of Baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study. Rheumatology. 2024;63(10):2799–2809.

27.

Baldi

, Parisi

, Falsetti

, . Efficacy and safety of upadacitinib in rheumatoid arthritis: real-life experience from a prospective longitudinal multicentric study. J Clin Med. 2024;13(2):401.

28.

Winthrop

, Tanaka

, Takeuchi

, . Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis. 2022;81(2):184–192.

29.

Aletaha

, Westhovens

, Combe

, . POS0676 efficacy and safety of filgotinib in patients aged ≥75 years: a post hoc subgroup analysis of the Finch 4 long-term extension (Lte) study. Ann Rheum Dis. 2022;81:612–613.

30.

Westhovens

, Alten

, Dagna

, . Safety and efficacy of filgotinib: an update from the Darwin 3 phase 2 long-term extension with a maximum of 8.2 years of exposure. Ann Rheum Dis, 2023;82:712–713.

31.

Kavanaugh

, Westhovens

, Winthrop

, . Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of phase II rheumatoid arthritis programs. J Rheumatol. 2021;48(8):1230–1238.

32.

Buch

, Verschueren

, Caporali

, . pos0658 Long-term efficacy of filgotinib monotherapy and combination therapy: interim results from a post hoc analysis of the Finch 4 study. Ann Rheum Dis. 2024;83:804–805.

33.

Combe

, Besuyen

, Gómez-Centeno

, . Geographic analysis of the safety and efficacy of filgotinib in rheumatoid arthritis. Rheumatol Ther. 2023;10:35–51.

34.

Atsumi

, Tanaka

, Matsubara

, . Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3). Mod Rheumatol. 2023;33(4):657–667.

35.

Tanaka

, Genovese

, Matsushima

. Long-term safety, efficacy, and patient-centered outcomes of filgotinib in the treatment of rheumatoid arthritis: current perspectives. Patient Prefer Adherence. 2023;17:2499–2516.

36.

Tanaka

, Kavanaugh

, Wicklund

, McInnes

. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: an overview from clinical trials. Mod Rheumatol. 2022;32(1):1–11.

37.

Kim

, Keam

. Filgotinib in rheumatoid arthritis: a profile of its use. Clin Drug Investig. 2021;41:741–749.

38.

Smolen

, Landewé

RBM

, Bergstra

, . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3–18.

39.

Papagoras

, Voulgari

, Drosos

. Long-term use of adalimumab in the treatment of rheumatic diseases. Open Access Rheumatol. 2009;1:51–68.

40.

Haraoui

, Bykerk

. Etanercept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag. 2007;3(1):99–105.

41.

Grimm

, Wijnen

, Riemsma

, . Filgotinib for moderate to severe rheumatoid arthritis: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2021;39(12):1397–1410.

42.

Angelini

, Talotta

, Roncato

, . JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future. Biomolecules. 2020;10(7):1002.

43.

Lindstrom

, Robinson

. Biomarkers for rheumatoid arthritis: making it personal. Scand J Clin Lab Invest Suppl. 2010;242:79–84.

44.

Shi

, Zhou

, Chang

, . Advancing precision rheumatology: applications of machine learning for rheumatoid arthritis management. Front Immunol. 202410;15:1409555.

45.

Justiz-Vaillant

, Soodeen

, Gopaul

, Arozarena-Fundora

, Akpaka

. The future directions of CAR-T cell therapy: unlocking the potential of immunotherapy in cancer treatment. Preprints. 2024, 2024060155.

Filgotinib: An Extensive Review of a Promising JAK Inhibitor in Rheumatoid Arthritis

Abstract

Keywords

Introduction

Importance of Effective Management to Prevent Joint Damage and Disability

Introduction to Janus Kinase Inhibitors

Mechanism of Action of Janus Kinase Inhibitors

Mechanism of Action of Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.

Overview of JAK Inhibitors Used in Rheumatoid Arthritis Treatment

Objectives of the Review

Assess the Efficacy of Filgotinib

Evaluate the Safety Profile of Filgotinib

Compare Filgotinib with Other RA Treatments

Identify Patient Subgroups Benefiting from Filgotinib

Highlight Gaps in Current Knowledge

Methodology

Methodology Overview of the Systematic Review Process.

Search Strategy

Inclusion and Exclusion Criteria

PRISMA Flow Diagram for the Selection of Studies in the Systematic Review of Filgotinib in Rheumatoid Arthritis.

Inclusion Criteria

Exclusion Criteria

Timeframe and Language Restrictions

Data Extraction and Synthesis

Data Extraction

Quality Assessment

Clinical Efficacy of Filgotinib

Efficacy End Points

Comparative Efficacy

Comparison with Traditional DMARDs

Summary

Comparison with Other JAK Inhibitors

Summary

Overall Comparison

Serious Infections and Outcomes with Filgotinib

Comparison with Tofacitinib and Other JAK Inhibitors

Long-term Efficacy

Safety and Tolerability

Types of Malignancies Linked to Filgotinib

Clinical Applications

Patient Populations

Combination Therapy

Monotherapy

Comparative Analysis

Comparative Analysis: Filgotinib versus Other JAK Inhibitors and Biologic DMARDs

Economic Considerations

Cost-effectiveness

Direct Cost

Indirect Cost

Comparative Effectiveness

Healthcare Utilisation

Future Directions

Ongoing Research

Personalised Medicine

Innovative Therapies

Potential Impact

Discussion

Conclusion

List of Abbreviations

Footnotes

Acknowledgements

Authors’ Contribution

Consent to Participate

Consent for Publication

Data Availability

Declaration of Conflicting Interests

Ethical Considerations

Funding Statement

References